Update as of 11 November 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on  Rotavirus Vaccine (live, attenuated) monovalent G1P[8] strain porcine circovirus (PCV) – free ended on 04 November 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted on 11 November 2025 to the Secretary of Health, pending decision.

As of 20 October 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment for the minor inclusion of rotavirus vaccine (live, attenuated) monovalent G1P[8] strain porcine circovirus (PCV) – free in the Philippine National Formulary (PNF) for the prevention of gastro-enteritis caused by rotavirus infection in children less than one (1) year of age. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 20 October to 04 November  2025.

As preliminary recommendation, the HTA Council positively recommends the government financing of rotavirus vaccine (live, attenuated) monovalent G1P[8] strain porcine circovirus (PCV) – free through its minor inclusion in the PNF.

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the advisory and the evidence document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 04 November 2025 (Tuesday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please contact us through the same email address.